Swiss drugmaker Novartis AG said Monday that its meningitis vaccine Menveo has been approved for use in teenagers and adults by the U.S. Food and Drug Administration. Menveo is a vaccine ... Read More
Iron Mountain said Monday that it is picking up Mimosa Systems in a deal worth $112 million. Mimosa specializes in enterprise content archiving systems. Iron Mountain focuses on data archiving, e-discovery ... Read More
Billionaire investor Carl Icahn is backing a startup company that would build trains to run on President Barack Obama’s high-speed rail network, challenging international manufacturers that dominate the market, the company ... Read More
Peabody Energy Corp. said today that it has signed an agreement with Cambridge, Mass.-based GreatPoint Energy to develop plants that would convert coal to synthetic gas and hydrogen. The number of ... Read More
Viasystems Group Inc. says it has completed its purchase of Merix Corp. in a deal that gives St. Louis one more publicly-traded company. Viasystems, based in Clayton, was privately held. Beaverton, ... Read More
J.D. Power and Associates rated KCI as the top medium-sized airport in its 2010 North America Satisfaction Study, released Thursday. Lambert-St. Louis International ranked as the 10th best medium-sized airport. J.D. ... Read More
A new type of nuclear reactor—smaller than a rail car and one tenth the cost of a big plant—is emerging as a contender to reshape the nation’s resurgent nuclear power industry. ... Read More
Experiments by scientists at the Pentagon’s Defense Advanced Research Projects Agency (DARPA) are moving forward quickly and could be producing jet fuel from algae at competitive prices by next year, the ... Read More
Delta Dental of Missouri has acquired Advantica EyeCare, a Clearwater, Fla.-based vision benefits provider with 2.4 million members nationwide and annual revenue in excess of $46 million. Financial terms weren’t closed. ... Read More
AstraZeneca waded into the competitive rheumatoid arthritis market on Tuesday by buying rights to Rigel Pharmaceuticals‘ next-generation drug R788 for up to $1.245 billion, Reuters reported. The deal is a big ... Read More